Avita Medical Announces Notice Of Allowance Of 2nd U.S. Patent Application

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - June 17, 2015) - Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/223,577. The allowed application is directed to the novel composition of matter in the form of an epithelial cell suspension, in connection with the Company's proprietary platform of regenerative products (ReCell®, ReNovaCell™ and ReGenerCell™).

"This newly allowed application further establishes our US patent coverage," commented Adam Kelliher, CEO of Avita. "Having a strong IP platform in place is a crucial part of our strategy as we work towards US regulatory approval, and entry into the market."

The allowed application provides broad protection for the autologous, non-cultured cell suspension prepared peri-operatively and directly applied to the patient. Avita has a robust intellectual property portfolio for its regenerative technology platform. ReCell®, ReGenerCell™ and ReNovaCell™ are protected by a family of patents and patent applications covering the unique composition of an epithelial suspension, method of production, device and automation for generating the epithelial suspension. Currently, pending worldwide patents and applications will expire in 2022-2034. Additional filings having a later expiration date will be made as Avita continues to invent in the regenerative medicine field.


Avita Medical (http://www.avitamedical.com) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.


Avita Medical Ltd
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
Email: akelliher@avitamedical.com

Avita Medical Ltd
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
Email: trooney@avitamedical.com

Avita Medical Ltd
Gabriel Chiappini
Company Secretary
Phone:+61(0) 8 9474 7738
Email: gabriel@laurus.net.au

Help employers find you! Check out all the jobs and post your resume.

Back to news